Fig. 5. (A) Comparison of the ability of Xbh1, Xbh1Vp16 and Xbh1EngR mRNA to activate the ganglion cell marker Xbrn3d in animal caps. RT-PCR analysis on animal caps injected with RNA from different Xbh1 wild-type and fusion constructs, as indicated. Injected amounts of RNA were 500 pg for each construct, either alone or in combination. (B-E) Lipofection experiments with Xbh1, Xbh1EngR and Xbh1Vp16 constructs. Embryos were lipofected with GFP+pCS2 vector (C), GFP+Xbh1 (D), GFP+Xbh1Vp16 (E) or GFP+Xbh1EngR (not shown), and retinae were analyzed at stage 42. The percent representation of each cell type was calculated as a weighted average±s.e.m. Counted cells were: n=2625 cells from six retinae for GFP; n=2908 cells from six retinae for Xbh1; n=2382 from 15 retinae for Xbh1EngR; and n=3707 cells from 19 retinae for Xbh1Vp16. Asterisks represent significant differences as determined by one-way analysis of variance with the Tukey-Kramer Multiple Comparisons Test as a post-test (^*P<0.05, ^***P<0.001).